Shares of biotech FibroGen (Nasdaq: FGEN) leapt 14.6% to $2.12 by close of trading Tuesday, after it announced a deal with UK pharma major AstraZeneca (LSE: AZN) for roxadustat would be terminated.
FibroGen and AstraZeneca have agreed to terminate the US/RoW roxadustat collaboration agreement entered into on July 30, 2013, under which AstraZeneca held development and commercialization rights in the USA and other territories outside of China not licensed to Astellas Pharma (TY: 4503).
AstraZeneca is returning all US/RoW roxadustat rights to FibroGen (with the exception of South Korea) and providing certain assistance during a transition period.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze